Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IRBs Punked Again: FDA Sends Warning Letter To Essex IRB For Approving Fictitious Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

In an operation highly reminiscent of a government sting three and a half years ago, "Dateline NBC" snares a for-profit IRB using a fictitious protocol.

You may also be interested in...



Who's Watching The Watchmen This Time? The Mystery Of The New IRB Sting

Institutional review boards appear to be facing vigilante regulation as FDA warns that someone is submitting fictitious studies for review.

IRB Quality Concerns Take Center Stage After FDA Clamps Down On Coast

Quality has moved up in importance as a criterion for selecting an institutional review board following an April 14 FDA warning letter to Coast IRB and the company's agreement to halt enrollment in clinical studies it monitors

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

PS072707

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel